When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
RVNC - Revance Therapeutics receives US FDA approval for DAXXIFY product
Revance Therapeutics Inc.
Biotechnology company Revance Therapeutics ( NASDAQ: RVNC ) said that the U.S. Food and Drug Administration has approved its DAXXIFY product for injection for the temporary improvement of moderate to severe frown lines in adults.
The peptide-formulated neuromodulator product's approval by the FDA is the first approval by the regulator for Revance.
For adverse reactions, the company said most commonly observed reactions were headache, eyelid ptosis and facial paresis.